Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00655564 · ClinicalTrials.gov registry record · Phase 4
Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis
A Phase 4 study, sponsored by Wake Forest University.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT00655564 is a Phase 4 study that has completed, run by Wake Forest University. The registered enrollment target is 15 participants.
The verdict
NCT00655564, a Phase 4 study, has completed, sponsored by Wake Forest University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this research study is to see how well the medication Alefacept (Amevive®) works for continuous treatment of chronic plaque psoriasis. The US Food and Drug Administration (FDA) has approved Alefacept in an intermittent dosage schedule of 15 mg weekly injection for 12 weeks followed by 12 weeks off treatment.
Interventions
- DRUG Alefacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2008-05 |
| Est. Completion | 2010-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00655564
The ClinicalTrials.gov registry entry for NCT00655564 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alefacept is the first listed.
NCT00655564 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00655564 about?
NCT00655564 is a clinical study titled "Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis". The purpose of this research study is to see how well the medication Alefacept (Amevive®) works for continuous treatment of chronic plaque psoriasis. The US Food and Drug Administration (FDA) has approved Alefacept in an intermittent dosage schedule of 15 mg weekly injection for 12 weeks followed by...
What is the current status of trial NCT00655564?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2008-05. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00655564?
The interventions under investigation include: Alefacept (DRUG).
Who is sponsoring clinical trial NCT00655564?
This trial is sponsored by Wake Forest University, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.